September 20, 2017
HOUSTON–(BUSINESS WIRE)–SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Australian Patent No. 2015202319, “Methods And Compositions For Repair of Cartilage Using An In Vivo Bioreactor.”
The technology described in the patent involves producing chondrocytes or chondrocyte-like cells using fibroblasts in vivo with mechanical stress and low oxygen tension.
“This Australian patent covers our core technology and provides the foundation for our intellectual property protection internationally. It solidifies our scientific basis and protects our technology in an extremely important market,” said Pete O’Heeron, Chief Executive Officer, SpinalCyte.
With this addition, SpinalCyte’s portfolio now includes 24 U.S. and foreign patents issued and directly owned by the company, along with 45 patents pending.
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. Currently, SpinalCyte holds 24 U.S. and international issued patents and has filed for an additional 45 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement.
Contacts
SpinalCyte, LLC
Investor Contact:
Pete O’Heeron, 281-461-6211
CEO
info@spinalcyte.com
